☆ 4.5 Article

Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1 & alpha;/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma

CANCER MANAGEMENT AND RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

New therapies for clear cell ovarian carcinoma

James Stewart et al.

Summary: Ovarian clear cell carcinoma is a rare subtype of ovarian cancer with unique features, including ARID1A mutations. Current treatments are based on trials for high grade serous ovarian cancer, and new treatment strategies targeting immune checkpoints, angiogenesis, and ARID1A interactions are being tested. However, predictive biomarkers and sequencing of treatments need further exploration.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma

Min Yin et al.

Summary: This study aimed to explore molecular alterations among OCCC patients with different chemotherapeutic responses and obtain insights into potential biomarkers. Gene expression analysis identified differentially expressed genes associated with platinum sensitivity in OCCC, providing a research basis for further exploration of targeted therapy.

BMC WOMENS HEALTH (2023)

添加到收藏夹

Article Oncology

High Levels of FGF11 Correlate with Poor Survival in Patients with Human Papillomavirus (HPV)-Positive Oropharyngeal Squamous Cell Carcinoma

Caroline Haglund de Flon et al.

Summary: In order to identify patients with HPV-positive OPSCC and a poor prognosis after treatment, the gene expression in tumours from patients with poor or favourable prognosis was compared in a case-control study. The results were validated on RNA and protein levels in two separate cohorts. High expression of FGF11 was associated with poor patient survival in all three cohorts. This suggests that FGF11 may be a major prognostic marker in HPV-positive OPSCC.

CANCERS (2023)

添加到收藏夹

Article

Fibroblast Growth Factor 11 Enables Tumor Cell Immune Escape by Promoting T Cell Exhaustion and Predicts Poor Prognosis in Patients with Lung Adenocarcinoma

Baoqian Zhai et al.

Journal of Oncology (2023)

添加到收藏夹

Article Oncology

Hypoxia promotes thyroid cancer progression through HIF1α/FGF11 feedback loop

Bo Chen et al.

Summary: Hypoxia is a crucial factor in promoting cervical lymph node metastasis and recurrence in thyroid cancer. The upregulation of FGF11 in hypoxic thyroid cancer cells and tissues, along with its positive feedback loop with HIF1α, enhances the growth and metastasis of thyroid cancer cells.

EXPERIMENTAL CELL RESEARCH (2022)

添加到收藏夹

Review Environmental Sciences

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer

Antonios Revythis et al.

Summary: Ovarian cancer is a common gynecologic cancer with high mortality rate. The standard treatment includes surgery and chemotherapy, but relapse is common. Mutations in BRCA1/2 genes are significant in ovarian cancer, and PARP inhibitors have shown effectiveness. Immune checkpoint inhibitors have limited success in ovarian cancer compared to other cancers.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

添加到收藏夹

Review Oncology

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

Stergios Boussios et al.

Summary: DNA damage is a hallmark of cancer. Epithelial ovarian cancer (EOC) and prostate cancer often have defects in DNA damage response (DDR) pathways. PARP inhibitors are a therapeutic strategy for EOC and prostate cancer, particularly in tumors with HR deficiency. Genetic testing plays an increasingly important role in the treatment of ovarian and prostate cancer patients.

CANCERS (2022)

添加到收藏夹

Article Oncology

The Tumor Microenvironment of Clear-Cell Ovarian Cancer

Michael-John Devilin et al.

Summary: The tumor microenvironment (TME) of clear-cell ovarian cancer (CCOC) was analyzed in this study, revealing differences in immune cell populations, collagen matrix, and cytokine expression between different areas of the tumor. Advanced CCOC showed increased fibroblasts and a more complex collagen matrix compared to early CCOC. Differences in immune cell populations, collagen matrix, and cytokine expression were also observed between different genetic subtypes of CCOC. Increased infiltration of specific T cell subpopulations was associated with decreased overall survival.

CANCER IMMUNOLOGY RESEARCH (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era

Aruni Ghose et al.

Summary: Identifying ovarian cancer at early stages is challenging due to its heterogeneity. Next-generation sequencing and proteomics analysis can provide insights into the disease's molecular biology and adaptive responses to therapy, leading to improved treatment choices and outcomes.

PROTEOMES (2022)

添加到收藏夹

Review Oncology

Clear cell carcinoma of the ovary: a clinical and molecular perspective

Yasushi Iida et al.

Summary: Clear cell carcinoma of the ovary has unique biological features and clinical manifestations. There are significant differences in incidence based on geography and race, with younger patients often presenting at early stages and having tumors associated with endometriosis. Specific gene mutations, such as ARID1A and PIK3CA, are common in this type of carcinoma.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Oncology

The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry

Nicholas Pavlidis et al.

Summary: This study aimed to determine the differential effect of treatment periods on the survival of patients with stage IV SPPC, fallopian tube cancers, and EOC. The results showed significant differences in cause-specific survival among different treatment eras, with treatment era and age at diagnosis being closely associated with cause-specific survival. Subgroup analyses of phase III randomized controlled trials by tumor subset may provide more insights into the effects of novel therapies.

CANCER EPIDEMIOLOGY (2021)

添加到收藏夹

Review Oncology

Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class

April Weaver et al.

Summary: Comprehensive genomic profiling plays an important role in cancer therapeutics, with frequent FGFR alterations in tumors being potential targets. Two FDA-approved medications are available for specific cancer types.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

添加到收藏夹

Review Oncology

HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies

Xin Wang et al.

Summary: Ovarian cancer is the eighth most commonly diagnosed cancer among women worldwide. HIF-1 alpha plays a crucial role in promoting malignant cell chemoresistance, tumour metastasis, angiogenesis, immunosuppression, and intercellular interactions in ovarian cancer, making it a potential therapeutic target.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma

Sachiko Kitamura et al.

Summary: Ovarian clear cell carcinoma (CCC) is associated with endometriosis, resistance to oxidative stress, and poor prognosis due to its resistance to standard chemotherapy. Chromosome 17q21-24 amplification is linked to recurrence and cisplatin resistance in CCC. High expression of pyruvate dehydrogenase kinase 2 (PDK2) is associated with worse prognosis, and inhibition of PDK2 enhances cisplatin sensitivity in ovarian CCC by targeting mitochondrial metabolism and redox homeostasis.

CANCER SCIENCE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets

Evangelia Ioannidou et al.

Summary: Prostate cancer is the most common cancer in men and despite therapeutic advances, many patients still cannot be cured. Antiagiogenic therapies have shown limited benefits for prostate cancer compared to other types of cancer. Clinical trials and treatments for refractory castration-resistant prostate cancer face challenges and further research is needed to better understand mechanisms of resistance.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway

Xiaowei Wu et al.

Summary: The study demonstrated that FGF11 acts as an oncogene in non-small cell lung cancer, while miR-525-5p may negatively regulate FGF11. Targeting FGF11 and HIF-1 alpha could serve as novel strategies for the treatment of NSCLC.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Review Immunology

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

Khalil Khalaf et al.

Summary: The tumor microenvironment (TME) is a complex and dynamic tissue containing various components such as blood supply, immune cells, and extracellular matrix, which together create an environment conducive to tumor cell growth and proliferation. Cellular crosstalk, cell-to-ECM communication, exosomes, and specific metabolic patterns play crucial roles in immune evasion and therapy resistance in the TME. In addition, characteristics like hypoxia, metabolic abnormalities, and mechanical forces further contribute to treatment resistance.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Obstetrics & Gynecology

Current and future strategies for treatment of ovarian clear cell carcinoma

Aiko Ogasawara et al.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies

Aleksandra Klemba et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Review Oncology

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option

M. Buechel et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

Xinming Jing et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Review Oncology

Future applications of FGF/FGFR inhibitors in cancer

Gaia Cristina Ghedini et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

FGF Family: From Drug Development to Clinical Application

Qi Hui et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

FGF11 induced by hypoxia interacts with HIF-1α and enhances its stability

Kyeong Won Lee et al.

FEBS LETTERS (2017)

添加到收藏夹

Article Oncology

Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma

Shu-Biao Ye et al.

JOURNAL OF PATHOLOGY (2016)

添加到收藏夹

Article Medicine, Research & Experimental

ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin

Changshuai Lyu et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)

添加到收藏夹

Review Oncology

Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives

Shinya Matsuzaki et al.

CANCER CELL INTERNATIONAL (2015)

添加到收藏夹

Article Oncology

Hypoxia-induced fibroblast growth factor 11 stimulates capillary-like endothelial tube formation

Jimin Yang et al.

ONCOLOGY REPORTS (2015)

添加到收藏夹

Article Oncology

Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11 -> miRNA-541 -> androgen receptor (AR) -> MMP9 signaling

Shuai Hu et al.

MOLECULAR ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis

Yue Jin et al.

TUMOR BIOLOGY (2014)

添加到收藏夹

Article Obstetrics & Gynecology

Aberrant Expression of the Mammalian Target of Rapamycin, Hypoxia-inducible Factor-1α, and Glucose Transporter 1 in the Development of Ovarian Clear-cell Adenocarcinoma

Masafumi Kato et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary

Ayako Kim et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2010)

添加到收藏夹

Article Oncology

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

Sunyoung Lee et al.

GYNECOLOGIC ONCOLOGY (2007)

添加到收藏夹

Article Obstetrics & Gynecology

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary

H Itamochi et al.

OBSTETRICS AND GYNECOLOGY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.